EN/中

C-Bridge Capital is a healthcare-dedicated private equity firm that invests in China-related opportunities

C-Bridge Capital is a healthcare-dedicated private equity firm that mainly invests in mature, leading businesses across China’s major healthcare sectors including pharmaceutical/ biotech, medical technology and healthcare services. C-Bridge Capital’s unique and sector-dedicated investment strategy targets lower risk platform companies with clear ability to expand business lines. Our current portfolio covers a number of sectors including bio-pharma, drug distribution, molecular diagnosis, medical devices and medical services.

Through utilizing its capital resources, C-Bridge Capital is committed to accelerating the R&D and commercialization of modern medical and pharmaceutical technologies, improving patient  health and the healthcare system for the benefit of all people.

Healthcare Focused

C-Bridge Capital is a healthcare-dedicated private equity firm, focused on middle & late-stage growth and buyout investment opportunities in China including the pharmaceutical/ biotech, medical technology and healthcare services sub-sectors.

Leading Team

C-Bridge Capital team comprises of a group of talented professionals including seasoned investors, senior executives and professionals from the healthcare industry, as well as professional legal and financial support.

Capital Support

C-Bridge Capital helps portfolio companies expand with assistance with capital needs. In addition, the team provides further value add with government and further resources so they can achieve/ extend commercialization and generate attractive returns for shareholders.

Shared Growth

C-Bridge Capital aims to achieve shared growth and alignment with portfolio companies through its specialist operating model, which includes assisting with operations management, team building, strategy formulation and business expansion.

Our Vision

Through utilizing its capital resources, C-Bridge Capital is committed to accelerating the R&D and commercialization of modern medical and pharmaceutical technologies that fulfill unmet medical needs, providing high-quality medical products in-line with international standards, improving the health and healthcare system for the benefit of all people, as well as achieving highly attractive returns for the firm’s investors.